Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(44.4%)

Phase 1

4(44.4%)

Phase 3

1(11.1%)

9Total

Phase 2(4)

Phase 1(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01048151Phase 1Unknown

TNFerade Biologic to Treat Locally Advanced Prostate Cancer

Role: lead

NCT00051467Phase 3Completed

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Role: lead

NCT00496236Phase 1Completed

Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer

Role: lead

NCT00496535Phase 1Completed

A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer

Role: lead

NCT00137878Phase 2Completed

TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer

Role: lead

NCT00215696Phase 2Completed

A Study to Treat Patients Whose Chronic Angina Symptoms Are Not Relieved by Medication and Have an Area of the Heart That Cannot be Treated by Standard Therapies

Role: lead

NCT00261404Phase 2Completed

TNFerade™ Biologic Plus Radiation for Metastatic Melanoma

Role: lead

NCT00051480Phase 2Completed

Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer

Role: lead

NCT00109499Phase 1Completed

Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)

Role: lead

All 9 trials loaded